| NCT02282345 | Breast Cancer | Drug: Talazoparib | M.D. Anderson Cancer Center|Medivation, Inc. | Phase 2 | 2015-04-01 | 2017-03-16 |
| NCT03070548 | Advanced Solid Tumors | Drug: Talazoparib | Medivation, Inc. | Phase 1 | 2016-10-01 | 2017-02-28 |
| NCT01286987 | Advanced or Recurrent Solid Tumors|Breast Neoplasms|Ovarian Cancer, Epithelial|Ewing Sarcoma|Small Cell Lung Carcinoma|Prostate Cancer|Pancreas Cancer | Drug: Talazoparib | Medivation, Inc. | Phase 1 | 2010-12-01 | 2016-03-09 |
| NCT03042910 | Solid Tumor | Drug: Talazoparib | Medivation, Inc. | Phase 1 | 2016-10-01 | 2017-02-01 |
| NCT02567396 | Estrogen Receptor Negative|Head and Neck Squamous Cell Carcinoma|HER2/Neu Negative|Hormone-Resistant Prostate Cancer|Metastatic Pancreatic Adenocarcinoma|Progesterone Receptor Negative|Solid Neoplasm|Stage III Mesothelioma|Stage IIIA Gastric Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Small Cell Lung Carcinoma|Stage IIIB Gastric Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Small Cell Lung Carcinoma|Stage IIIC Gastric Cancer|Stage IIIC Ovarian Cancer|Stage IV Mesothelioma|Stage IV Non-Small Cell Lung Cancer|Stage IV Ovarian Cancer|Stage IV Small Cell Lung Carcinoma|Triple-Negative Breast Carcinoma | Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Talazoparib | National Cancer Institute (NCI) | Phase 1 | 2016-07-01 | 2017-02-06 |
| NCT02997163 | Advanced Solid Tumors | Drug: Talazoparib | Medivation, Inc. | Phase 1 | 2017-01-01 | 2016-12-15 |
| NCT02997176 | Advanced Solid Tumors | Drug: Talazoparib | Medivation, Inc. | Phase 1 | 2016-11-01 | 2016-12-15 |
| NCT02286687 | Advanced Cancers | Drug: Talazoparib Tosylate|Behavioral: Phone Call | M.D. Anderson Cancer Center|BioMarin Pharmaceutical | Phase 2 | 2014-12-22 | 2017-02-06 |
| NCT02401347 | Advanced Breast Cancer|HER2/Neu Negative|Triple-Negative Breast Cancer | Drug: Talazoparib Tosylate | Melinda Telli|National Cancer Institute (NCI)|Stanford University | Phase 2 | 2015-08-01 | 2015-08-09 |
| NCT02034916 | Breast Neoplasms|BRCA 1 Gene Mutation|BRCA 2 Gene Mutation | Drug: talazoparib | Medivation, Inc.|Myriad Genetic Laboratories, Inc. | Phase 2 | 2014-01-01 | 2016-12-13 |
| NCT02836028 | Ovarian Cancer | Drug: Talazoparib|Drug: Temozolomide | Medivation, Inc.|Myriad Genetic Laboratories, Inc. | Phase 2 | 2016-10-01 | 2016-12-20 |
| NCT02878785 | Acute Myeloid Leukemia | Drug: Decitabine|Drug: talazoparib | University of Maryland|Medivation, Inc. | Phase 1|Phase 2 | 2016-08-01 | 2016-08-21 |
| NCT02627430 | Adult Solid Neoplasm|Estrogen Receptor Negative|Fallopian Tube Serous Neoplasm|HER2/Neu Negative|Ovarian Serous Adenocarcinoma|Ovarian Serous Tumor|Primary Peritoneal Serous Adenocarcinoma|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Triple-Negative Breast Carcinoma | Drug: Hsp90 Inhibitor AT13387|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Talazoparib | National Cancer Institute (NCI) | Phase 1 | 2016-03-01 | 2016-07-22 |
| NCT02392793 | Childhood Solid Tumors | Drug: Talazoparib|Drug: Irinotecan|Drug: Temozolomide|Drug: Filgrastim|Drug: Peg-filgrastim | St. Jude Children's Research Hospital|BioMarin Pharmaceutical|Alliance Pharma|Pfizer | Phase 1 | 2015-03-16 | 2017-02-08 |
| NCT02921919 | Cancer | Drug: Talazoparib | Medivation, Inc. | Phase 2 | 2016-09-01 | 2017-01-31 |
| NCT02317874 | Solid Neoplasm | Drug: Carboplatin|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel|Other: Pharmacological Study|Drug: Talazoparib | National Cancer Institute (NCI) | Phase 1 | 2015-07-01 | 2017-03-22 |
| NCT01945775 | Breast Neoplasms|BRCA 1 Gene Mutation|BRCA 2 Gene Mutation | Drug: talazoparib|Drug: Physician's-Choice | Medivation, Inc. | Phase 3 | 2013-10-01 | 2016-12-08 |
| NCT02537561 | Solid Tumors|Carcinoma, Non-Small Cell Lung|Non-Small Cell Lung Cancer|Non-Small-Cell Lung Carcinoma|Nonsmall Cell Lung Cancer | Drug: Cisplatin|Drug: Gemcitabine|Drug: Talazoparib | Washington University School of Medicine|BioMarin Pharmaceutical | Phase 1 | 2015-12-01 | 2016-02-10 |
| NCT02116777 | Adult Solid Neoplasm|Childhood Solid Neoplasm|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Refractory Central Nervous System Neoplasm | Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Talazoparib|Drug: Temozolomide | National Cancer Institute (NCI) | Phase 1|Phase 2 | 2014-05-01 | 2017-03-22 |
| NCT02316834 | Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer | Drug: BMN 673 | M.D. Anderson Cancer Center|BioMarin Pharmaceutical|National Cancer Institute (NCI) | Early Phase 1 | 2015-06-01 | 2017-02-24 |
